Coadministration of ethinylestradiol (00.35 mg once daily), norethindrone (1 mg once daily) and rilpivirine had no effect on ethinylestradiol AUC or Cmin, but increased Cmax by 17%; there was no change in norethindrone AUC, Cmin or Cmax. Based on historic controls, there was no change in rilpivirine AUC, Cmin or Cmax. Coadministration of ethinylestradiol (0.025 mg once daily), norgestimate (0.180/0.215/0.250 mg once daily) and emtricitabine/tenofovir alafenamide (200/25 mg once daily) had no effect on the AUC, Cmin and Cmax of norelgestromin, norgestrel or ethinylestradiol. No dose adjustment is required.
Odefsey Summary of Product Characteristics, Gilead Sciences Ltd, January 2019

Based on drug interaction studies conducted with the fixed dose combination or components of Odefsey, no clinically significant drug interactions have been either observed or expected when Odefsey is combined with ethinylestradiol/norethindrone. Coadministration of ethinylestradiol/norethindrone (0.035/1 mg once daily) and rilpivirine (25 mg once daily) was studied in 17 subjects. Based on historical controls, there was no change in rilpivirine Cmax, AUC and Cmin (data from 15 subjects). Ethinylestradiol Cmax, AUC and Cmin increased by 17%, 14% and 9%; norethindrone Cmax, AUC and Cmin decreased bu 6%, 11% and 1%. Based on drug interaction studies conducted with the fixed dose combination or components of Odefsey, no clinically significant drug interactions have been either observed or expected when Odefsey is combined with ethinylestradiol/norgestimate.
Odefsey US Prescribing Information, Gilead Sciences Inc, October 2018.